Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...
Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...
A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...
This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...
The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...
AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...
In the second and final part of her interview with The American Journal of Managed Care ® (AJMC ®), Cherie Daly, MD, director ...
A rebate-driven formulary model allegedly incentivized higher insulin list prices, affecting three PBMs controlling roughly ...
Minnesota’s $515 million quarterly withholding and subsequent $1.3 billion deferral signal a more punitive federal stance that could normalize aggressive liquidity controls over state Medicaid ...
Prevalence is high (≈1:200–300 C282Y homozygotes; ≈1:8–10 carriers), but penetrance is incomplete, complicating broad screening policy and payer coverage decisions. Nonspecific presentations (fatigue, ...
Once-weekly 500 mg subcutaneous initiation is delivered by autoinjector as two 250 mg injections, allowing self- or caregiver administration at home rather than clinic-based IV starts. FDA acceptance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results